Pharmacy Benefits in 2026: Built on Transparency, Stewardship, and Strategies That Perform
As pharmacy costs continue to rise, employers and their broker partners are under increasing pressure to navigate complexity, manage uncertainty,…
Insights Archive
DRUG SPOTLIGHT Wegovy Tablets (semiglutide)
ManufacturerNovo Nordisk FDA Approval Date12/22/2025 The two new indications for oral semaglutide are in combination with a reduced calorie diet…
Inside ClearScript: 2025’s Wins, Breakthroughs & What’s Ahead
Join us as we discuss ClearScript’s 2025 highlights such as new member lives, implementation success rates, client satisfaction, and innovative new PBM products that were launched and those that are in the pipeline.
Compliance and Industry Update – November 2025
At ClearScript, we are committed to keeping you informed and prepared for the evolving landscape of Pharmacy Benefit Management (PBM). This update highlights key regulatory changes, industry updates, and ClearScript’s proactive strategies.
Your Guide to Managing Trend in 2026
If you’re managing pharmacy benefits in 2026, you’re likely facing rising costs, new therapies, and tough decisions. So how do you stay ahead? It starts with understanding what drives trend and how to manage it with confidence.
DRUG SPOTLIGHT: Centanafadine
Centanafadine is a novel, first-in-class, non-stimulant under development for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children, adolescents, and adults. It’s rapid onset & good safety profile would likely result in uptake for patients who do not respond to generic stimulant / non-stimulant therapy options.
Cutting Through the Cost Confusion: Understanding PBM Pricing and Cost Plus Models
In this Coffee with ClearScript episode, Reese Puckett, VP of PBM Operations, explains how pricing benchmarks work, what cost-plus really means, and the actual solutions to controlling pharmacy spend.
Managing PBM Trend in 2026: Your Need-to-Know Guide
Learn how your organization can stay ahead of the curve while managing costs and prioritizing member health.
DRUG SPOTLIGHT: Yeztugo® (lenacapavir)
A new formulation of lenacapavir has been developed for preexposure prophylaxis (PrEP) against HIV-1 infection. Yeztugo provides protection with only two annual injections. Gilead is also in the process of developing a once-yearly formulation of Yeztugo.
You Deserve More Than Reporting — And That’s Exactly What We Deliver
How ClearScript Partners With You to Improve Plan Performance, Not Just Measure It. At ClearScript, we’re proud to serve as more than just your pharmacy benefit manager. We’re your partner in navigating a complex and constantly evolving pharmacy landscape. And while robust reporting is a key part of our service, it’s only the beginning.
CASE STUDY: Managing the costs and health of a patient with rheumatoid arthritis
Putting Patients First: A Collaborative Approach to Managing Rheumatoid Arthritis and Reducing Costs.
Leveraging Therapy Management in Your Health Plan
ClearScript & Fairview Specialty Pharmacy’s Innovative Partnership Gain expert insight into Fairview and ClearScript’s approach to therapy management. Learn how…